Ventrus Biosciences, Inc. (Nasdaq: VTUS) 55.3% LOWER; today reported that its Phase 3, randomized, double-blind, placebo-controlled clinical trial of iferanserin ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE